Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2020 | Advantages of biomarker blood tests for Alzheimer’s diagnosis

Suzanne Schindler • 23 Jul 2020
AAIC 2020
Alzheimer’s Disease Dementia

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, explains how many patients may have memory impairment symptoms, but the cause is unknown. Thus, having a blood test would improve the diagnostic tools for dementia as it would be an option that is not as expensive as an amyloid PET scan or invasive as a spinal tap. This interview was recorded during an online conference with The Video Journal of Dementia (VJDementia).

More from Suzanne Schindler

1:27
Prioritizing diversity in Alzheimer’s disease biomarker studies
Suzanne Schindler • 18 Jul 2023
1:20
Blood-based brain-derived tau in Alzheimer’s disease
Suzanne Schindler • 19 Jul 2023
2:53
Roadblocks to the use of blood-based biomarkers in clinical care
Suzanne Schindler • 19 Jul 2023
0:56
Blood-based biomarkers for treatment monitoring in Alzheimer’s disease
Suzanne Schindler • 19 Aug 2023

Related Videos

2:33
Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark
Dorota Religa • 22 Mar 2024
0:50
Will long-term anti-amyloid treatment show greater clinical benefit?
Dorota Religa • 22 Mar 2024
1:24
Digital frailty screening in dementia
Dorota Religa • 22 Mar 2024
4:19
Current projects from Alzheimer’s Disease International
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals